SCHEMBL7113247

SCHEMBL7113247

Nc1nc(=O)c2c(ncn2Cc2ccc3ccccc3c2)n1Cc1ccc(O)c(O)c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PNP P00491 2/20 0.39
ADORA2A P29274 1/20 0.39
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HIF1A Q16665 1/20 0.38
FBP1 P09467 2/20 0.36
PDE10A Q9Y233 1/20 0.36
INSR P06213 2/20 0.36
IGF1R P08069 2/20 0.36
MEN1 O00255 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
KMT2A Q03164 1/20 0.35
ESR1 P03372 1/20 0.35
BACE1 P56817 2/20 0.35
VDR P11473 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7111074 0.93 PNP (0.44) PNPADORA2AALDH1A1SMN1; SMN2HIF1A
SCHEMBL7120152 0.89 PNP (0.45) PNPADORA2AALDH1A1SMN1; SMN2HIF1A
SCHEMBL7111860 0.87 PNP (0.45) PNPADORA2AALDH1A1SMN1; SMN2HIF1A
SCHEMBL7117280 0.87 PNP (0.45) PNPADORA2AALDH1A1SMN1; SMN2HIF1A
SCHEMBL7113168 0.86 PNP (0.43) PNPADORA2AALDH1A1SMN1; SMN2MEN1
SCHEMBL7113849 0.86 PNP (0.43) PNPADORA2AALDH1A1SMN1; SMN2MEN1
SCHEMBL7110374 0.86 SMN1; SMN2 (0.48) PNPADORA2ASMN1; SMN2PDE10AMAPK1
SCHEMBL7113866 0.86 PNP (0.39) PNPADORA2AALDH1A1SMN1; SMN2HIF1A
SCHEMBL7113948 0.85 PNP (0.42) PNPADORA2AALDH1A1SMN1; SMN2MEN1
SCHEMBL7118322 0.85 PNP (0.39) PNPADORA2AALDH1A1SMN1; SMN2HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030186978-A1 Novel telomerase inhibitors PHARMACIA ITALIA, SPA (IT) 2003-10-02 US claimed
US-20030186978-A1 Novel telomerase inhibitors PHARMACIA ITALIA, SPA (IT) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186978-A1 Novel telomerase inhibitors TERT, TERF2IP, TERF2 PNP 646/4885ADORA2A 4414/4885ALDH1A1 2360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.